Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
Mark N. Polizzotto, Jacqueline Nordwall, Abdel G. Babiker, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 530-540
Open Access | Times Cited: 66

Showing 26-50 of 66 citing articles:

Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 4
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
Hillary A. Vanderven, Stephen J. Kent
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 4
Analysis of 52 240 source plasma donors of convalescent COVID‐19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation
Amy E. Schmidt, Vogel Peter, Carrie A. Chastain, et al.
Journal of Clinical Apheresis (2022) Vol. 37, Iss. 5, pp. 449-459
Open Access | Times Cited: 7
Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)
Irini Sereti, Kathryn Shaw‐Saliba, Lori E. Dodd, et al.
PLoS ONE (2022) Vol. 17, Iss. 9, pp. e0273914-e0273914
Open Access | Times Cited: 7
Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
Julie M. Fox, Vicky Roy, Bronwyn M. Gunn, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Convalescent Plasma and Other Antibody Therapies for Infectious Diseases—Lessons Learned from COVID-19 and Future Prospects
David J. Sullivan
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Denise Battaglini, Fernanda F. Cruz, Chiara Robba, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 995-1015
Closed Access | Times Cited: 6
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial
Andrea Alemany, Pere Millat-Martínez, Marc Corbacho-Monné, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101898-101898
Open Access | Times Cited: 3
Convalescent Plasma Versus Hyperimmune Immunoglobulins
Daniele Focosi, Massimo Franchini, Emanuele Nicastri, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1356-1357
Closed Access | Times Cited: 3
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Junzheng Wu, Huichuan Yang, Ding Yu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 3
Passive antibody therapy in emerging infectious diseases
Xiaoming Yang
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1117-1134
Closed Access | Times Cited: 3
Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing’s Syndrome: A Case Report and Review of Literature
Bojana Popović, Aleksandra Radovanović Spurnić, Jelena Veličković, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 5
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population level
Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study
Sean Liu, Mila Mirceta, Grace Lin, et al.
Antimicrobial Agents and Chemotherapy (2023)
Open Access | Times Cited: 2
Measuring maternal improvement through multi-stakeholder engagement: Documenting developments in the dynamic programmatic context of the global COVID-19 pandemic through outcome harvesting
Rafael Dal‐Ré, Teck Chuan Voo, Søren Holm
Journal of Global Health (2023) Vol. 13
Open Access | Times Cited: 2
Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis
Meixuan Li, Yan-fei Li, Xin Xing, et al.
Inflammopharmacology (2023) Vol. 32, Iss. 1, pp. 335-354
Closed Access | Times Cited: 2
High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
Cynthia So‐Osman, Sarah J Valk
The Lancet (2022) Vol. 399, Iss. 10324, pp. 497-499
Open Access | Times Cited: 3
Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product
Elżbieta Lachert, Joanna Lasocka, Artur Bielawski, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1328-1328
Open Access | Times Cited: 3
Recent Hybrid Plasma Better Neutralizes Omicron Sublineages Than Old Hyperimmune Serum
Daniele Focosi, Michael J. Joyner, Arturo Casadevall
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. 554-554
Closed Access | Times Cited: 3
Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
А. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, et al.
Safety and Risk of Pharmacotherapy (2022) Vol. 10, Iss. 4, pp. 326-344
Open Access | Times Cited: 3
Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study
Sammy Huygens, Tim Preijers, Francis Swaneveld, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Clinical trial experience in Japan and future issues in developing drugs to treat COVID-19
Ayako Mikami, Junko Terada-Hirashima, Daisuke Tokita, et al.
Global Health & Medicine (2023) Vol. 5, Iss. 2, pp. 85-91
Open Access | Times Cited: 1
Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies.
David E. McIntosh, Thierry Burnouf, Michael Karbiener, et al.
PubMed (2023) Vol. 21, Iss. 5, pp. 375-377
Closed Access | Times Cited: 1
Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era
Dong Won Baek, Ga‐Young Song, Ho Sup Lee, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access

Scroll to top